{ "week": "2026-W29", "label": "Week 29 \u2014 July 19\u201325, 2026", "week_start": "2026-07-19", "generated": "2026-07-23", "stats": { "total_entries": 815, "new_this_week": 159, "compounds_represented": 9 }, "by_compound": { "psilocybin": [ { "id": "6298efb729c11d2a2d5f4ba9c3c6105674a109339b176dfe543c98fd2497b433", "title": "Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-09", "outcome_summary": null, "doi": "10.64898/2026.07.05.736652", "url": "https://pubmed.ncbi.nlm.nih.gov/42465498/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Psychedelic drugs show remarkable potential for treating psychiatric disorders, but the mechanisms underlying their therapeutic effects remain relatively unknown.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin used to treat psychiatric disorders, mechanism of action.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "70f89d5ab282228530b71750b8a8705bfe1646f73788ed8dce96cad6a8b47b5a", "title": "Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "PTSD", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1177/02698811261464988", "url": "https://pubmed.ncbi.nlm.nih.gov/42460632/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "When administered alongside monitoring and support, psilocybin has shown promise in the treatment of multiple psychiatric conditions. However, the contribution and nature of participant support in the context of psychedelic trials are much debated.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for PTSD treatment in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e4e30bce4dbb4b29373b6a598ce7604f1d451aa623c8f32cc6d0090934f059a3", "title": "Psilocybin's effect on human brain synaptic plasticity.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1038/s41398-026-04285-y", "url": "https://pubmed.ncbi.nlm.nih.gov/42457666/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiological mechanisms and impact of environmental context remain unclear.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin's effect on human brain synaptic plasticity.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "d62189447e9b1c0e09d990186f83d2364a9ea542b842688f2cecfe52904c2b9f", "title": "Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1136/bmjopen-2026-118471", "url": "https://pubmed.ncbi.nlm.nih.gov/42442821/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Bipolar II disorder (BD-II) is characterised by hypomanic and depressive episodes with the latter tending to dominate the clinical course of the disorder, and they are often associated with suicidality.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for bipolar II depression in a human feasibility study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "cda7ee30813a15220d247f9f53e5440eb902393274f8c9799b5ca3b0e88c07d8", "title": "Psilocybin-induced behavioral and cellular effects.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1080/01677063.2026.2695462", "url": "https://pubmed.ncbi.nlm.nih.gov/42437560/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Psilocybin, a prominent psychedelic, recently emerged as a potential therapeutic agent for psychiatric disorders, yet the molecular and cellular mechanisms driving its effects remain poorly understood.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin as a therapeutic agent for psychiatric disorders.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "7a72bbcd041048cac5695833ded37467591ce4dc2e8311c035b9028fb4f3e20a", "title": "The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation", "compound": "psilocybin", "type": "phase_2", "institution": "Sheppard Pratt Health System", "condition": "depression", "sample_size": 20, "status": "completed", "date": "2022-03-28", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05220410", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression and suicidal ideation", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "cd8bd231756ad97f3d86cc709d89fd6589f807ebc9477d5f89497d6a4d0230f6", "title": "The RECAP2 Study: Midazolam and Psilocybin", "compound": "psilocybin", "type": "phase_1", "institution": "University of Wisconsin, Madison", "condition": "other", "sample_size": 60, "status": "recruiting", "date": "2025-08-07", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06692192", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.\u2026", "relevance": { "relevant": true, "reason": "Study on psilocybin's effects on emotional wellbeing and neuroplasticity.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "55ed5ad93725f88c68404fb8cb674cc1f9a797195b26093be2a41edea6faf6ee", "title": "Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)", "compound": "psilocybin", "type": "phase_2", "institution": "TRYP Therapeutics", "condition": "other", "sample_size": 14, "status": "active", "date": "2024-01-17", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06206265", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for IBS, a chronic pain condition.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "741c96cee02d7dfc43a070d7b67926e6896fff83c54170e83397af0ea61b167c", "title": "Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects", "compound": "psilocybin", "type": "phase_1", "institution": "University Hospital, Basel, Switzerland", "condition": "depression", "sample_size": 27, "status": "completed", "date": "2019-07-04", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03912974", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research. Selective serotonin reuptake inhibitors (SSRIs) like escitalopram are first-line treatments for depression. They inhibit the serotonin transporter (SERT).\u2026", "relevance": { "relevant": true, "reason": "Psilocybin effects in healthy subjects, psychiatric research context.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "3cd9c0e957962c2515ef3c938a22b99c2c4a783b3eea89660d92d2f9bd760bca", "title": "Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN", "compound": "psilocybin", "type": "phase_2", "institution": "Unity Health Toronto", "condition": "other", "sample_size": 30, "status": "recruiting", "date": "2025-03-05", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06731335", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "This is a feasibility study to examine the use of use of Psilocybin (magic mushrooms) to alleviate pain in chronic neuropathic pain. While theoretical mechanisms demonstrate promise, there is no clinical evidence.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for chronic neuropathic pain in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "9a81e7ff1c6b2bef17921c2cb1a8a77648343f4e5f251d82245b96aa58a74112", "title": "Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects", "compound": "psilocybin", "type": "phase_1", "institution": "Medical University of Vienna", "condition": "depression", "sample_size": 85, "status": "recruiting", "date": "2025-11-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07490353", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are: Primary Objectives 1.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for anhedonia in depression patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e1a738f0600a2d3a38bcf86cf79ffcaef79aad77af09c7e3c003572530ab2afb", "title": "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression", "compound": "psilocybin", "type": "phase_3", "institution": "VA Office of Research and Development", "condition": "depression", "sample_size": 240, "status": "recruiting", "date": "2026-07-30", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07226232", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (\u00b1) concurrent posttraumatic stress disorder.", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "8355b10d43b68c7b85acd72a2d6743cc5f8f1ebbd46ee637a53ac7df47aade99", "title": "Persisting Effects of Psilocybin", "compound": "psilocybin", "type": "phase_1", "institution": "Johns Hopkins University", "condition": "other", "sample_size": 13, "status": "completed", "date": "2017-07-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02971605", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The proposed pilot study will assess whether ingestion of a classic hallucinogen (psilocybin) leads to changes in emotion processing and neural circuitry that may predict repeated self-administration of this drug and underlie an atypical mechanism of abuse liability, which may vitally contribute to the understanding of the potential for abuse and the underlying mechanisms supporting abuse of classic hallucinogens.", "relevance": { "relevant": true, "reason": "Psilocybin for potential abuse liability in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "f4fd9a8398680114762a1de4c2ae2970ad2574de875e7833e9a414796806fae7", "title": "Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept", "compound": "psilocybin", "type": "phase_2", "institution": "University of Zurich", "condition": "depression", "sample_size": 55, "status": "completed", "date": "2019-03-11", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03715127", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "Effects of serotonin 2A/1A receptor stimulation by psilocybin on mood and emotion processing in major depressive disorder: a randomized double-blind placebo-controlled study", "relevance": { "relevant": true, "reason": "Psilocybin for depression in humans, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "f5a54fa0f727ed1b50c340cb04181e9eb6716074bb792e13d3cade05389df23b", "title": "Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers", "compound": "psilocybin", "type": "phase_2", "institution": "Robin Carhart-Harris, PhD, MA", "condition": "other", "sample_size": 120, "status": "recruiting", "date": "2024-10-20", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06626139", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "One hundred twenty healthy participants, ages 21 to 70, who experience moderate-to-lower-than-average mental well-being will be evenly randomized into four different study arms, using a 2x2 factorial design.\u2026", "relevance": { "relevant": true, "reason": "Human study with psilocybin in healthy volunteers", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "b7e5679f9a57e0bca71428c67d68b87099d14b968025a93362ac4d6277892754", "title": "Safety Profile of Psilocybin for Cocaine Use Disorder", "compound": "psilocybin", "type": "observational", "institution": "University of California, Los Angeles", "condition": "other", "sample_size": 10, "status": "active", "date": "2029-02-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06102434", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for cocaine use disorder, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "3438621983d0eaf096922502b1cdf6ad0eef523bdd42646e24ed34dee7e4c289", "title": "A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers", "compound": "psilocybin", "type": "phase_1", "institution": "MycoMedica Life Sciences PBC", "condition": "other", "sample_size": 20, "status": "completed", "date": "2025-07-28", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07050368", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple doses of MLS101 in healthy participants.", "relevance": { "relevant": true, "reason": "Human study of psilocybin for psychiatric conditions.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "313f93269d74ac357fbf8c1f967d99cb838fd1d57cba00dcd51e21950e33a8bf", "title": "Psilocybin as serotonergic therapy in epilepsy: Narrative review of potentials and limitations.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-02", "outcome_summary": null, "doi": "10.1002/bcp.70690", "url": "https://pubmed.ncbi.nlm.nih.gov/42482371/", "source": "PubMed", "first_seen": "2026-07-22", "abstract": "Psilocybin shows potential in neuropsychiatric disorders but has a complex relationship with epilepsy and seizures. We reviewed literature up to November 2025 to identify studies relevant to psilocybin's effects on seizures and epilepsy, including our research on serotonergic modulation.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin therapy for epilepsy, a neurological disorder.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "9a93be986ea4d9747a853a8e8b40e6c08638efbe08d99281f257d49b51df1356", "title": "Psilocybin in Chronic Low Back Pain and Depression", "compound": "psilocybin", "type": "phase_1", "institution": "Johns Hopkins University", "condition": "depression", "sample_size": 40, "status": "recruiting", "date": "2024-04-22", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06355414", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose).\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for chronic pain and depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "bcfca1aa4f0d72ec026c795109243d94e9a127b90fda559c78ec6045764eb26e", "title": "The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder", "compound": "psilocybin", "type": "phase_2", "institution": "Maryland Oncology Hematology, PA", "condition": "depression", "sample_size": 30, "status": "active", "date": "2020-09-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04593563", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "This is a Phase II, single-center, fixed dose, open label trial to explore the safety, tolerability and efficacy of a 25mg dose of psilocybin in cancer patients with MDD. The study population will include adult men and women, 18 years of age or above, with MDD, diagnosed with a malignant neoplasm.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for depression in cancer patients is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "0a8bc3d25dbfb291bf36db0eda0dfaf237151f859853bb1835bb1c33cb2677c2", "title": "Psilocybin Therapy for Psychological Distress in Palliative Patients", "compound": "psilocybin", "type": "phase_2", "institution": "University Medical Center Groningen", "condition": "depression", "sample_size": 108, "status": "recruiting", "date": "2025-07-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06782724", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin therapy for psychological distress in palliative patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "bc4fd2b8858658e28bbedf2abaaf96c3b5ef1d98e7936db77cc18ee8e417504a", "title": "Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder", "compound": "psilocybin", "type": "phase_2", "institution": "Brigham and Women's Hospital", "condition": "addiction", "sample_size": 36, "status": "recruiting", "date": "2026-06-15", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07296094", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for alcohol use disorder in a human clinical trial.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "49c6c72dee296afba8eb55fd7e632fb453260b3d8215055b8b6bbac33dbb4981", "title": "Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.", "compound": "psilocybin", "type": "phase_1", "institution": "Francisco A Moreno", "condition": "OCD", "sample_size": 30, "status": "recruiting", "date": "2026-05-18", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07347405", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for OCD is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e847b99050c01ff37508c835fea374807c44944be93bca5b449f94180d188978", "title": "An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)", "compound": "psilocybin", "type": "phase_2", "institution": "Sheppard Pratt Health System", "condition": "depression", "sample_size": 27, "status": "active", "date": "2021-03-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04433858", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "7a2705208c25f2ab27d1c019c986d708b2f1edc547811e9ac1146c2c2bea413f", "title": "Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life", "compound": "psilocybin", "type": "phase_1", "institution": "Charles Raison", "condition": "other", "sample_size": 50, "status": "recruiting", "date": "2026-12-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07719088", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose/meaning in life in medically stable older adults.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin effects on healthy aging biomarkers and purpose in life.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "0bbeeda984b93fe5486086a7a4f207a60b40b8384956faf35cc9c5ae2d357009", "title": "Psilocybin-assisted CBT for Depression", "compound": "psilocybin", "type": "phase_1", "institution": "University of California, Los Angeles", "condition": "depression", "sample_size": 16, "status": "completed", "date": "2023-06-27", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05227612", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for depression, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "8abf55b93b6175f41831ab43f780301850bdb38b040f72bf90177a1492f588d8", "title": "Psilocybin After Trauma Surgery for Pain", "compound": "psilocybin", "type": "phase_1", "institution": "Trent Emerick", "condition": "addiction", "sample_size": 70, "status": "recruiting", "date": "2026-07-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07406828", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The goal of this clinical trial is to evaluate whether a single dose of psilocybin is feasible and safe for adults with opioid use disorder (OUD) who are recovering from trauma surgery. The main questions it aims to answer are: 1.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for pain and opioid use disorder in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "25d885c3fcdb93dfd3f089a4f5e61580ccc624cc750e559a4a414cd3140b109a", "title": "A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients", "compound": "psilocybin", "type": "observational", "institution": "The Roots to Thrive Society for Psychedelic Therapy", "condition": "other", "sample_size": 64, "status": "active", "date": "2023-09-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05958758", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The purpose of the study is to understand the feasibility of a resilience focused community of practice program that includes psilocybin-assisted therapy for End-of-Life Distress.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin-assisted therapy for end-of-life distress.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "730022941b6ae67cd24c53bcb91c89d34df7fb9d9e6fe2a263e244ffa6b1669c", "title": "Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder", "compound": "psilocybin", "type": "phase_3", "institution": "Khyber Medical University Peshawar", "condition": "depression", "sample_size": 60, "status": "recruiting", "date": "2026-04-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07703722", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "Trauma-related Major Depressive Disorder (MDD) is frequently associated with poor response to conventional antidepressants, persistent psychological distress, and alterations in gut-brain axis function.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for depression and gut-brain axis biomarkers.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "c5717a9e98373ee79a83d56b494326e073b121f8295813d4d4126e32e44177e0", "title": "Bioavailability Study of Psilocybin in Normal Adults", "compound": "psilocybin", "type": "phase_1", "institution": "University of Wisconsin, Madison", "condition": "other", "sample_size": 0, "status": "completed", "date": "2023-06-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05467761", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The purpose of this research study is to compare an oral dose of psilocybin and an intravenous (IV) infusion of psilocybin to assess differences in how the drug is absorbed by the body, the psychedelic experience, and any side effects when taken by healthy adult participants.\u2026", "relevance": { "relevant": true, "reason": "Human study on psilocybin bioavailability and experience.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "2ae68af507da4bef9d888d2002b6b38928c337a24fcd53d746c10c0c8fa6491e", "title": "Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)", "compound": "psilocybin", "type": "phase_2", "institution": "Nathan Brashares Sackett", "condition": "PTSD", "sample_size": 40, "status": "recruiting", "date": "2025-06-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06853912", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "This study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for treatment of approximately 40 military veterans and first responders (ages 21-65) with co-occurring alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD).\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for PTSD and AUD in veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "1a6353e43c74ccec2cf72efc85a6d71336482fe5f9b332a0e79c328fa5c38e49", "title": "Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study", "compound": "psilocybin", "type": "observational", "institution": "Johns Hopkins University", "condition": "addiction", "sample_size": 82, "status": "completed", "date": "2008-09-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01943994", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "One of the most promising lines of investigation for the therapeutic use of hallucinogens in the 1960s and 1970s was in the treatment of drug dependence.\u2026", "relevance": { "relevant": true, "reason": "Psilocybin for addiction treatment in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "5be1a712f46e37f225bc261bd3bc50cf297a3c9ca66f91c271937a17abfb8aac", "title": "The psychedelic renaissance has a new owner: big pharma", "compound": "psilocybin", "type": "news", "institution": "FDA", "condition": "other", "sample_size": null, "status": "active", "date": "2026-06-24", "outcome_summary": "The Trump executive order granted FDA priority vouchers to three psychedelic programs\u2014Compass Pathways and Usona for synthetic psilocybin, and Transcend Therapeutics for methylone\u2014signaling a shift toward pharmaceutical development of psychedelics, while leaving religious and community uses untouched.", "doi": null, "url": "https://chacruna.net/the-psychedelic-renaissance-has-a-new-owner-big-pharma/", "source": "Chacruna Institute", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Big pharma investment in psychedelic drug development.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "8b1a7a3c5b669919c0c835390a85c7fbb1fbdd444837c72e33455c4b709d1b7f", "title": "Comp360 psilocybin treatment in TRD with antidepressants", "compound": "psilocybin", "type": "news", "institution": "Compass Pathways", "condition": "depression", "sample_size": 200, "status": "active", "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://compasspathways.com/our-work/comp360-psilocybin-treatment-in-trd-with-antidepressants", "source": "Compass Pathways", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression (TRD).", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "2ae5c4d60d1df48e3c77aec04fc439ee9be13e41670ad99efed64855e2ea82d8", "title": "About psilocybin therapy and treatment", "compound": "psilocybin", "type": "news", "institution": "Compass Pathways", "condition": "depression", "sample_size": 1450, "status": "active", "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://compasspathways.com/our-work/about-psilocybin-therapy-and-treatment", "source": "Compass Pathways", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Psilocybin therapy for psychiatric treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "ddf4503ab7ccf7a07ce82744ac8a3f5eb7e686bb2d0c338af1a8dcc8be0fccca", "title": "Post-traumatic stress disorder (PTSD)", "compound": "psilocybin", "type": "news", "institution": "Compass Pathways", "condition": "PTSD", "sample_size": null, "status": "other", "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://compasspathways.com/our-work/post-traumatic-stress-disorder-ptsd", "source": "Compass Pathways", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Psychiatric indication: PTSD", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e61431981641612c85ae94dd087c2985a227b2429bb845666a1471ed2fec5a73", "title": "The market for psychedelic drugs to treat mental health conditions gets a big buy signal", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways", "condition": "depression", "sample_size": 200, "status": "published", "date": "2026-07-22", "outcome_summary": "In a phase 3 trial, psilocybin\u2011assisted therapy produced clinically significant and sustained improvement in depression scores, with about 60% of participants achieving remission at 4 weeks.", "doi": "10.1038/s41591-022-01907-5", "url": "https://www.cnbc.com/2026/07/19/psychedelic-drugs-mental-health.html", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Psychedelic drug for depression treatment in human trial.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "71af2b76c5a4fd422067250bd935b87334e1ea0672163793a88ee2cdaffa2985", "title": "Phase 2 Study of Psilocybin for Treatment-Resistant Depression", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "recruiting", "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07247006", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "ed2a8b8ad498e1a863d53fa459af53a03978597846793b7db8eaafde40fb9a2a", "title": "Psychedelics Research and Psilocybin Therapy", "compound": "psilocybin", "type": "news", "institution": "Johns Hopkins Center for Psychedelic and Consciousness Research", "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-22", "outcome_summary": "Johns Hopkins has led psilocybin research, demonstrating safety and therapeutic potential in anxiety and smoking cessation, and has obtained regulatory approval to resume research with healthy volunteers.", "doi": null, "url": "https://www.hopkinsmedicine.org/psychiatry/research/psychedelics-research", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Psilocybin therapy for anxiety and smoking cessation in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "5491acad1412ebfd7f7e404f555592fcbaaa9937f88865c68ddf4f6ae4a68ba1", "title": "Psychedelic Science @ Cornell", "compound": "psilocybin", "type": "news", "institution": "Cornell University", "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-22", "outcome_summary": "Phase II trials of psilocybin\u2011assisted psychotherapy have shown efficacy in treating major depression, with durable reductions in symptoms after one or two dosing sessions.", "doi": "10.1038/s41593-022-01177-4", "url": "https://psychedelics.cornell.edu", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Psilocybin for major depression in human trials.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "73b35e00ab6f675fc1b13e78eec1733055f6cd2fda7d389bb52461f22dcb901e", "title": "Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans", "compound": "psilocybin", "type": "phase_1", "institution": "University of Zurich", "condition": "other", "sample_size": 122, "status": "completed", "date": "2023-10-24", "abstract": "The study looks into whether administering psychedelic substances that stimulate the serotonin system influences pro-social behavior when compared to administering substances that stimulate the dopamine system in healthy individuals.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06081179", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Human study on serotonin system stimulation and pro-social behavior.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "521bff96e9178be75d3d987b10e8a80b3af611dbf420aa811b70a1837ddd8594", "title": "The Neurobiological Effect of 5-HT2AR Modulation", "compound": "psilocybin", "type": "phase_1", "institution": "Gitte Moos Knudsen", "condition": "other", "sample_size": 200, "status": "recruiting", "date": "2017-03-03", "abstract": "The investigators wish to investigate neurobiological effects of serotonin 2A receptor modulation in healthy volunteers, contrasting effects of an agonist (psilocybin) and an antagonist (ketanserin).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03289949", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Human study on psilocybin's neurobiological effects.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "501d36d641160bd70b9c36ddd29f57361c136abe88fdb363e7866516dd44bc91", "title": "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder", "compound": "psilocybin", "type": "phase_2", "institution": "COMPASS Pathways", "condition": "depression", "sample_size": 102, "status": "active", "date": "2023-01-30", "abstract": "Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05733546", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Phase II study of COMP360 for major depressive disorder.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "0185a2514e7c423c9635b37e3898cff24c0d3315a7439c0fd23218219ef26c70", "title": "Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)", "compound": "psilocybin", "type": "phase_1", "institution": "Beckley Psytech Limited", "condition": "other", "sample_size": 4, "status": "completed", "date": "2021-08-11", "abstract": "This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04905121", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Psilocybin for chronic headache in a human study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "d97406896ac9f2017d93acd94342117eb0157cec577545631e2cf3c93c31d425", "title": "The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training", "compound": "psilocybin", "type": "observational", "institution": "Felix Mueller", "condition": "other", "sample_size": 48, "status": "recruiting", "date": "2022-10-25", "abstract": "The study investigates two groups of participants of the S\u00c4PT therapist's training starting in October 2022.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05570708", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Therapist training for substance-assisted therapy", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "99ab60e6221bb396eefe4cf9a091bf5322ddd48e4bf3be307268d7de6635c733", "title": "PsilOCD: A Pharmacological-Challenge Feasibility Study", "compound": "psilocybin", "type": "phase_1", "institution": "Imperial College London", "condition": "OCD", "sample_size": 19, "status": "completed", "date": "2022-10-28", "abstract": "The purpose of this study is to assess the impact of psilocybin on cognitive inflexibility and neural plasticity in a cohort of people with obsessive-compulsive disorder (OCD).", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06258031", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Psilocybin for OCD is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "6e44dbcbabb5cb93c7ff0e8089f96ae760396161f2111a0025360590f90a7c20", "title": "Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity", "compound": "psilocybin", "type": "preprint", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-04-24", "abstract": "BackgroundPsilocybin is a classic psychedelic that acutely alters brain functional connectivity. These changes are linked to therapeutic doses and subjective effects, with some evidence that changes persist beyond acute drug administration.\u2026", "outcome_summary": null, "doi": "10.64898/2026.04.17.26351147", "url": "https://doi.org/10.64898/2026.04.17.26351147", "source": "bioRxiv/medRxiv", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Human study on psilocybin's effects on brain connectivity.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "663b4f91c4defa8505a82c016484b05fe2c8ad0f4771aa3b910680d48db7e13d", "title": "Psilocybin-facilitated Treatment for Cocaine Use", "compound": "psilocybin", "type": "news", "institution": "University of Alabama at Birmingham", "condition": "addiction", "sample_size": null, "status": "other", "date": "2025-12-18", "abstract": "above-identified clinical trial, titled \u201cPsilocybin-facilitated Treatment for Cocaine Use.\u201d It appears that results information for the referenced applicable clinical trial has not been submitted to the ClinicalTrials.gov data bank.5 You should review your records of this clinical trial and determine whether you submitted all required results information.\u2026", "outcome_summary": "The FDA has identified potential noncompliance related to the clinical trial titled \"Psilocybin-facilitated Treatment for Cocaine Use\" because results information appears to have not been submitted to the ClinicalTrials.gov data bank. The responsible party is urged to review records and submit any required results information promptly.", "doi": null, "url": "https://www.fda.gov/media/190608/download", "source": "FDA Press Releases", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "FDA action on psilocybin for cocaine use disorder treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "9bc1c13742c96489b4b2fa93962bca1d3f8558eeaddd43ae3cd221138eb43b9d", "title": "Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": null, "status": "active", "date": "2026-02-17", "abstract": "\u201cAcross three robust, well-designed and well-executed clinical trials involving more than 1,000 participants, we have now demonstrated consistent, highly statistically significant results at the primary endpoint and a clinically meaningful effect.\u2026", "outcome_summary": "The second Phase 3 trial (COMP006) evaluating COMP360 psilocybin for treatment-resistant depression met its primary endpoint, showing a statistically significant reduction in symptom severity compared to placebo. Data across multiple trials suggest a rapid onset, durable effect, and a generally well-tolerated safety profile.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx", "source": "Compass Pathways", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Phase 3 trial of psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "5ad0bd1a5dc2994443d6b6eee95fb6d6f2c2b931c59ff50c33f09199450a8df1", "title": "COMP360 psilocybin treatment in TRD", "compound": "psilocybin", "type": "phase_2", "institution": "Compass Pathways", "condition": "depression", "sample_size": 233, "status": "published", "date": "2023-07-24", "abstract": "Our randomised controlled phase 2b study of investigational psilocybin treatment in treatment-resistant depression is the largest psilocybin treatment clinical trial ever conducted, with 233 patients across 22 sites in 10 countries across Europe and North America.\u2026", "outcome_summary": "A single 25mg dose of COMP360 psilocybin, with psychological support, showed a statistically significant reduction in depressive symptoms after three weeks, with a durable response up to 12 weeks.", "doi": "10.1056/NEJMoa2206443", "url": "https://compasspathways.com/our-work/comp360-psilocybin-treatment-in-trd", "source": "Compass Pathways", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression (TRD).", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "7b5d0516365051387dbc75392ae16a83302271971439d4615b0931a28a362d46", "title": "COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology", "compound": "psilocybin", "type": "phase_2", "institution": "COMPASS Pathways", "condition": "depression", "sample_size": 19, "status": "published", "date": "2023-07-17", "abstract": "Results: Dr. Guy Goodwin, Chief Medical Officer at COMPASS Pathways, said, \u201cIt has long been thought that SSRIs could interfere with the potential therapeutic effect of psilocybin.\u2026", "outcome_summary": "Positive data from an open-label phase 2 clinical trial of COMP360 psilocybin in addition to daily SSRIs in treatment-resistant depression was published. The trial suggests patients could remain on their SSRI antidepressant medication and experience the same effect from COMP360 psilocybin treatment as people who are not on SSRIs.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2023/COMPASS-Pathways-announces-publication-of-positive-data-from-treatment-resistant-depression-phase-2-clinical-trial-of-COMP360-psilocybin-alongside-antidepressants-in-Nature-journal-Neuropsychopharmacology/default.aspx", "source": "Compass Pathways", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "4a6ff312746aa899b2e6d03f6a8afcee462b89f635fdb87f9b37c8ffc6b7d9ee", "title": "Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder", "compound": "psilocybin", "type": "phase_2", "institution": "Compass Pathways plc", "condition": "PTSD", "sample_size": 22, "status": "published", "date": "2025-09-02", "abstract": "consistent with the preliminary results to date; the results of early-stage clinical trials of our investigational COMP360 psilocybin treatment in PTSD may not be predictive of the results of our planned late-stage clinical trial in PTSD; our need for substantial additional funding to achieve our business goals and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our clinical trials; our efforts to obtain marketing [...] \u201cAffecting approximately 13 million people in the U.S., and with only two approved treatments in the past two decades, post-traumatic stress disorder (PTSD) represents an area of profound unmet need with limited innovation to date,\u201d said Dr.\u2026", "outcome_summary": "A Phase 2 study evaluating COMP360 psilocybin in 22 patients with PTSD showed it was well tolerated and indicated rapid and durable improvement in symptoms from baseline observed out to 12 weeks following a single administration.", "doi": "10.1177/02698811251362390", "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Publication-of-Results-from-Phase-2-Study-of-COMP360-Psilocybin-for-Post-Traumatic-Stress-Disorder/default.aspx", "source": "Compass Pathways", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Phase 2 study of psilocybin for PTSD in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "1f649008b2359a49196650be047c6f067a1bb299eb530d272a86b94a5f29346e", "title": "Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression", "compound": "psilocybin", "type": "observational", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": 66, "status": "published", "date": "2025-03-18", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the results of early-stage clinical trials of our investigational COMP360 psilocybin treatment may not be predictive of the results of later stage clinical trials, including that the results from [...] The pivotal phase 3 clinical program of COMP360 psilocybin treatment in TRD is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted.\u2026", "outcome_summary": "The COMP004 study, a 52-week observational follow-up of previous trials, found that a single 25 mg dose of COMP360 psilocybin demonstrated a longer maintenance of antidepressant effects compared to 1 mg and 10 mg doses in patients with treatment-resistant depression.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Publication-of-Results-from-COMP004-Study-on-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx", "source": "Compass Pathways", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression study results.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "58542da6aa5c6efb14df56081df3cbb086450ed636f2446d8bf68f5334dcc109", "title": "Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": 600, "status": "active", "date": "2026-07-07", "abstract": "of more than 3 years on average and a history of over 6 lifetime episodes.\u2026", "outcome_summary": "The second Phase 3 trial (COMP006) for COMP360 (synthetic psilocybin) in treatment-resistant depression (TRD) showed that 39% of participants in the 25 mg arm achieved a clinically meaningful reduction in MADRS score by week 6 and maintained it through week 26. The data confirms a rapid onset and durable profile, with a generally well-tolerated safety profile.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/default.aspx", "source": "Compass Pathways", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Phase 3 trial of psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "aa84a2dbac97fea789d1492f82485c88821249280d0cd7ff81002086c5433ea6", "title": "Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": 258, "status": "active", "date": "2025-06-23", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the full results and safety data from this Phase 3 study in TRD or the results and safety data from our second Phase 3 study in TRD, COMP006, may not be consistent with the preliminary results to [...] \u201cThe positive top-line results at week 6 from the COMP005 trial underscore the innovative potential of psilocybin treatment in mental health care for which Compass Pathways continues to pave the way,\u201d said Kabir Nath, Chief Executive Officer of Compass Pathways.\u2026", "outcome_summary": "The first Phase 3 trial (COMP005) evaluating COMP360 psilocybin for treatment-resistant depression met its primary endpoint, showing a statistically significant and clinically meaningful reduction in symptom severity compared to placebo at 6 weeks. The trial involved 258 participants.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx", "source": "Compass Pathways", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Phase 3 trial of psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "ccb22d89b7744962e1efe6e2fa93d22a960f93548f41772151aa32cc23e468e0", "title": "Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy", "compound": "psilocybin", "type": "phase_2", "institution": "Compass Pathways plc", "condition": "PTSD", "sample_size": null, "status": "published", "date": "2026-07-16", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the results of early-stage clinical trials of our investigational COMP360 psilocybin treatment in PTSD may not be predictive of the results of our planned late-stage clinical trial in PTSD; our [...] Key Findings & Qualitative Themes These findings were published in the Journal of Psychopharmacology.\u2026", "outcome_summary": "A post-hoc analysis of a Phase 2 study of COMP360 psilocybin treatment in PTSD patients showed minimal interaction between participants and support providers during sessions. Patient-reported monitoring and support were linked to presence and reassurance, distinguishing it from conventional psychotherapy.", "doi": "10.1177/02698811261464988", "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Publication-of-Post-Hoc-Analysis-Demonstrating-Distinction-of-COMP360-Trial-Monitoring--Support-from-Psychotherapy/default.aspx", "source": "Compass Pathways", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Psilocybin for PTSD treatment in human study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "fc8bb19af70f2415b01f0ac27f5c90eb3c6a833e91d661bd8bf6ee9842fe9c31", "title": "Magic mushrooms may reshape the brain long after the trip ends", "compound": "psilocybin", "type": "observational", "institution": "University of California - San Francisco", "condition": "other", "sample_size": 28, "status": "published", "date": "2026-07-22", "abstract": ": A single dose of psilocybin produced measurable changes in brain activity and possible changes in brain structure that lasted for up to a month.\u2026", "outcome_summary": "A single dose of psilocybin produced measurable changes in brain activity and possible changes in brain structure that lasted for up to a month. Participants who experienced the greatest increase in flexible, varied brain activity also reported more personal insight and later improvements in well-being.", "doi": null, "url": "https://www.sciencedaily.com/releases/2026/07/260719040005.htm", "source": "General News", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Human study on psilocybin's effects on brain structure and well-being.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "23e5ba261127cad495bd01d5f3c1937dec4774f93b4e33231fbb1bb4fb4397b0", "title": "Magic mushrooms may reshape the brain long after the trip ends", "compound": "psilocybin", "type": "observational", "institution": "University of California - San Francisco", "condition": "other", "sample_size": 28, "status": "published", "date": "2026-07-22", "abstract": ": A single dose of psilocybin produced measurable changes in brain activity and possible changes in brain structure that lasted for up to a month.\u2026", "outcome_summary": "A single dose of psilocybin produced measurable changes in brain activity and possible changes in brain structure that lasted for up to a month. Participants who experienced the greatest increase in flexible, varied brain activity also reported more personal insight and later improvements in well-being.", "doi": "10.1038/s41467-026-28700-z", "url": "http://www.sciencedaily.com/releases/2026/07/260719040005.htm", "source": "General News", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Human study on psilocybin's effects on brain structure and well-being.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } } ], "mdma": [ { "id": "91add29a845bc20b517e849813871cb85e5eecef49190d41d4a4a43212b86f7b", "title": "MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD", "compound": "mdma", "type": "phase_3", "institution": "Dr. Leslie Morland", "condition": "PTSD", "sample_size": 16, "status": "completed", "date": "2023-10-06", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05979844", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The goal of this pilot trial is to examine the preliminary effectiveness of MDMA-facilitated bCBCT for improving chronic PTSD and relationship functioning in a sample of veterans and their intimate partners seeking care within the VA San Diego Healthcare System.", "relevance": { "relevant": true, "reason": "MDMA for PTSD in veterans is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "fff7a23d0dd29532ef68d51381db23faa575326c283bc8a4c1f5262972c05fe8", "title": "Approval is not access: a postcard from psychedelic Europe", "compound": "mdma", "type": "regulatory", "institution": "Resilient Pharmaceuticals", "condition": "PTSD", "sample_size": null, "status": "other", "date": "2026-06-30", "outcome_summary": "The FDA issued a complete response letter rejecting Lykos Therapeutics' MDMA\u2011assisted therapy application for PTSD.", "doi": null, "url": "https://www.lucid.news/approval-is-not-access-a-postcard-from-psychedelic-europe/", "source": "Lucid News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Regulatory decision on MDMA-assisted therapy for PTSD.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "32722772322bcce5161e29b0a7f815e9d1f4e4d82d5b74706e90178b7fbb8d20", "title": "In Brief: ICER Issues Final Evidence Report and Recommendations Re: MDMA-Assisted Therapy; Lykos Responds", "compound": "mdma", "type": "news", "institution": "Institute for Clinical and Economic Review", "condition": "PTSD", "sample_size": null, "status": "published", "date": "2026-07-22", "outcome_summary": "ICER\u2019s final evidence report concluded that current data are insufficient to demonstrate a net health benefit of MDMA\u2011assisted therapy for PTSD, and it could not provide a price benchmark, while recommending a robust REMS program and oversight by independent societies. The report also urged that any approval be accompanied by comprehensive risk mitigation and provider certification.", "doi": null, "url": "https://psychedelicalpha.com/news/in-brief-icer-issues-final-evidence-report-and-recommendations-re-mdma-assisted-therapy-lykos-responds", "source": "Psychedelic Alpha", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Regulatory news about MDMA-assisted therapy for PTSD.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "09296cf0622abbeac26cbe8105e620e6bb4c6620972b6f278bfbac7779e72f2e", "title": "Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD", "compound": "mdma", "type": "news", "institution": "Dutch advisory committee", "condition": "PTSD", "sample_size": null, "status": "other", "date": "2026-07-22", "outcome_summary": "The Dutch advisory committee recommends that the government expedite the therapeutic use of MDMA for treating patients with PTSD.", "doi": null, "url": "https://psychedelicalpha.com/news/dutch-committee-seeks-to-expedite-mdma-assisted-therapy-for-ptsd", "source": "Psychedelic Alpha", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "ce7829a867dcdb1d33eb139ef83c33f3fcd69f1534dc98669c41887cdd0f717f", "title": "Australian Federal Government Funds Trial of MDMA-Assisted Therapy for Individuals Affected by Northern River Floods", "compound": "mdma", "type": "news", "institution": "Southern Cross University", "condition": "PTSD", "sample_size": null, "status": "recruiting", "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://psychedelicalpha.com/news/australian-federal-government-funds-trial-of-mdma-assisted-therapy-for-individuals-affected-by-northern-river-floods", "source": "Psychedelic Alpha", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for trauma related to natural disaster.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "925e1ddc4b934a465f2d979e55629d72a87e2fad418609e15501a283f5e7c3b1", "title": "Live Coverage: FDA Advisory Committee Reviews MDMA-Assisted Therapy for PTSD", "compound": "mdma", "type": "news", "institution": "Lykos Therapeutics", "condition": "PTSD", "sample_size": null, "status": "other", "date": "2026-07-22", "outcome_summary": "The FDA advisory committee voted 10\u20111 that MDMA\u2011assisted therapy\u2019s benefits do not outweigh its risks for PTSD, and 9\u20112 that the available data do not demonstrate effectiveness.", "doi": null, "url": "https://psychedelicalpha.com/news/live-coverage-fda-advisory-committee-reviews-mdma-assisted-therapy-for-ptsd", "source": "Psychedelic Alpha", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "FDA review of MDMA-assisted therapy for PTSD", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "077ac75aafd6abfbd2b149495b77a9d81d152ac64a260fcfd5cb2b1ca053b794", "title": "Exclusive: Therapists and Trialists from Lykos\u2019 Phase 3 MDMA-Assisted Therapy Studies Push Back on ICER\u2019s Critical Draft Report", "compound": "mdma", "type": "news", "institution": "Lykos Therapeutics", "condition": "PTSD", "sample_size": null, "status": "active", "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://psychedelicalpha.com/news/exclusive-therapists-and-trialists-from-lykos-phase-3-mdma-assisted-therapy-studies-push-back-on-icers-critical-draft-report", "source": "Psychedelic Alpha", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Industry news about MDMA-assisted therapy trials.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "da158c4ac55d68d728b02528dd4139cecc0b51ed74430a5538c96c690ce2c194", "title": "MDMA Trials for PTSD in Soldiers: What to Know Now", "compound": "mdma", "type": "phase_3", "institution": "Veterans Affairs (VA)", "condition": "PTSD", "sample_size": null, "status": "active", "date": "2026-07-22", "outcome_summary": "Phase 3 trial data reviewed by the FDA show significant reductions in symptom severity for treatment\u2011resistant PTSD; trials are ongoing and FDA approval is pending.", "doi": null, "url": "https://valoannetwork.com/mdma-trials-ptsd-soldiers", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "MDMA for PTSD in human soldiers, FDA review.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "f55256d1b357185e41dd9c081659a0e25e1ce27f86b35a743d8d5835f350d535", "title": "MDMA PTSD FDA Decision 2026", "compound": "mdma", "type": "regulatory", "institution": "FDA", "condition": "PTSD", "sample_size": null, "status": "approved", "date": "2026-07-22", "outcome_summary": "The FDA approved MDMA\u2011assisted therapy for PTSD in 2026.", "doi": null, "url": "https://www.1800medicalsupply.com/blog/mdma-ptsd-fda-decision-2026", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "FDA decision on MDMA-assisted therapy for PTSD.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "0141f4b7e5480512a2a7037c92abfc39d867605a3fbe61c19431a568c75cbe7d", "title": "Implementation factors shaping British Columbia's drug decriminalization pilot: A systematic review with narrative synthesis.", "compound": "mdma", "type": "meta_analysis", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-07-21", "abstract": "In January 2023, British Columbia (BC) became the first Canadian province to implement a legally sanctioned drug decriminalization policy, removing criminal penalties for adults possessing 2.5 g or less of opioids, cocaine, methamphetamine, and MDMA.\u2026", "outcome_summary": null, "doi": "10.1016/j.drugpo.2026.105431", "url": "https://pubmed.ncbi.nlm.nih.gov/42480418/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Drug decriminalization policy and its implementation factors.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e9b82f8ceed1a13765621a81bc6618074e5952e149c165bf88fe4ff9b077cd05", "title": "Drug Effects on Interpersonal Interaction", "compound": "mdma", "type": "observational", "institution": "University of Chicago", "condition": "other", "sample_size": 30, "status": "completed", "date": "2021-08-01", "abstract": "The investigators propose to use a Paired Partner design, in which subjects engage in a 45-min semi-structured conversation with one (novel) partner under the influence of MDMA and with another partner under the influence of placebo.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05123716", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "MDMA effects on interpersonal interaction in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "dad907e4e686b39de48facaac4cc64372d9e3a6ceb46a04fd6c9a848a79000e4", "title": "Effect of Stimulant Drugs on Social Perception", "compound": "mdma", "type": "phase_1", "institution": "University of Chicago", "condition": "other", "sample_size": 36, "status": "completed", "date": "2016-06-01", "abstract": "The study will improve our understanding of the \"prosocial\" effects of \u00b1 3,4-Methylenedioxymethamphetamine (MDMA), relative to a prototypical stimulant, methamphetamine (MA). The investigators seek to characterize the \"uniquely social\" effects of MDMA.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03790618", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "MDMA's prosocial effects in humans are relevant to psychiatric treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "ea20ec2dcd3222b04b488334f9b22f40f40efbc1dcc21da04286f89cab3a7fbb", "title": "BREAKING: FDA Publishes Lykos Therapeutics\u2019 MDMA Complete Response Letter (CRL)", "compound": "mdma", "type": "regulatory", "institution": "Lykos Therapeutics", "condition": "PTSD", "sample_size": null, "status": "approved", "date": "2025-09-04", "abstract": "## BREAKING: FDA Publishes Lykos Therapeutics\u2019 MDMA Complete Response Letter (CRL) * Post published:September 4, 2025 This morning, FDA announced that it will now release complete response letters (CRLs) \u201cpromptly after they are issued to sponsors.\u201d Alongside that announcement, it released 89 previously unpublished CRLs that were issued since 2024.\u2026", "outcome_summary": "The FDA issued a Complete Response Letter (CRL) to Lykos Therapeutics, rejecting their MDMA for PTSD application due to issues with adverse event reporting, lack of durability data, and potential selection bias. The FDA suggested a new clinical trial to address these concerns.", "doi": null, "url": "https://psychedelicalpha.com/news/breaking-fda-publishes-lykos-therapeutics-mdma-complete-response-letter-crl", "source": "Psychedelic Alpha", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "FDA decision on MDMA for PTSD treatment", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "5967daaa41112b03548aa2cbceca3dae383cf6f6fee2ac159f1dd68843ce9204", "title": "Jupiter Neurosciences enters the psychedelic space with $100 million MDMA deal", "compound": "mdma", "type": "news", "institution": "Jupiter Neurosciences", "condition": "other", "sample_size": null, "status": "other", "date": "2026-07-21", "abstract": "# Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug. Jupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for the U.S. rights to an MDMA drug to treat neuropsychiatric disorders.\u2026", "outcome_summary": "Jupiter Neurosciences has entered the psychedelic drug development space by acquiring exclusive rights to MDMA-based treatments for PTSD from a private company. The deal is valued at up to $100 million.", "doi": null, "url": "https://www.fiercebiotech.com/biotech/jupiter-neurosciences-enter-psychedelic-space-100-million-mdma-deal", "source": "General News", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Industry news about MDMA for PTSD treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } } ], "ketamine": [ { "id": "b3caf75b4a6fba9b34663268c91eccfc5b303e9a37200d1ead3b9ba9d171269e", "title": "Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1016/j.euroneuro.2026.112907", "url": "https://pubmed.ncbi.nlm.nih.gov/42468081/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Esketamine nasal spray (NS) is an established treatment for patients with treatment resistant depression (TRD). To further optimise real-world outcomes, consensus is needed regarding strategies to enhance patient outcomes and decision-making factors for pivotal timepoints in esketamine NS treatment.\u2026", "relevance": { "relevant": true, "reason": "Esketamine for treatment resistant depression", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "c7984bd02c8655e9f7b43f780ac1dc5ca375c60b5dbe67c732fb28631b6d9d5f", "title": "Case Report: Intranasal esketamine and accelerated intermittent theta-burst stimulation for severe treatment-resistant depression with suicidal ideation.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-01-01", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1837402", "url": "https://pubmed.ncbi.nlm.nih.gov/42466185/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Treatment-resistant major depressive disorder with high-risk suicidal ideation is a psychiatric emergency that requires rapid and effective intervention.\u2026", "relevance": { "relevant": true, "reason": "Psychiatric indication: treatment-resistant depression with suicidal ideation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e03368195f3f72b31120d4f6cbccc21fe5cc2b61a7d5fd91e7b0d1152187d8bc", "title": "Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1016/j.jad.2026.122265", "url": "https://pubmed.ncbi.nlm.nih.gov/42462931/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Ketamine and its enantiomer esketamine are efficacious in 30-35% of the patients with treatment-resistant depression (TRD). Increased serum brain-derived neurotrophic factor (BDNF) following treatment has been proposed as a potential biomarker of antidepressant response.\u2026", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "562807cb65e29946b18c8175ce99c361413b55116f96a54d7d910df6c8654c98", "title": "Autonomic-salience stability as a candidate Gate for awake low-dose ketamine: a systems neuroscience framework with a clinical anchor.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-01-01", "outcome_summary": null, "doi": "10.3389/fnsys.2026.1880737", "url": "https://pubmed.ncbi.nlm.nih.gov/42459755/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Ketamine responses vary across patients and sessions, suggesting that dose alone is an incomplete organizing principle.\u2026", "relevance": { "relevant": true, "reason": "Low-dose ketamine for autonomic-salience stability framework.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "34f1e34e130595e4a59cfe8686494ea00112a7189beffc32798200946ba7b1f7", "title": "Ketamine use disorder: A case report.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2025-09-01", "outcome_summary": null, "doi": "10.14744/DAJPNS.2025.00294", "url": "https://pubmed.ncbi.nlm.nih.gov/42459236/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": null, "relevance": { "relevant": true, "reason": "Ketamine use disorder is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "44bc7ee277f72bf96212e59f0e0066de0a282cba64a25305682bd0bc1dc7da6f", "title": "Innovative integration of high dose ketamine infusion, psychological services, and specialized multidisciplinary pain care for refractory pain syndromes.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1080/17581869.2026.2696883", "url": "https://pubmed.ncbi.nlm.nih.gov/42454590/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate receptor that has garnered significant interest as a treatment for both chronic pain and mental health symptoms in the last two decades.\u2026", "relevance": { "relevant": true, "reason": "Ketamine for refractory pain syndromes and mental health symptoms.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "669d07a7383542356f731ea683ecc8b3ad47def74eadae5e9ac4078293d45ee9", "title": "Erratum to: Calcium/Calmodulin-Dependent Protein Kinase II and Eukaryotic Elongation Factor 2 Kinase Pathways Mediate the Antidepressant Action of Ketamine.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1016/j.biopsych.2026.06.020", "url": "https://pubmed.ncbi.nlm.nih.gov/42446461/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": null, "relevance": { "relevant": true, "reason": "Antidepressant action of ketamine in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "0b4e9b3e4fda8b03d4d3006acc24d5b6f1201566d2afaee51e7eb81975c7e8da", "title": "L-tetrahydropalmatine attenuates ketamine reward effect via modulating the miR-27a-3p/MAP2K4 axis.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-01-01", "outcome_summary": null, "doi": "10.3389/fgene.2026.1701742", "url": "https://pubmed.ncbi.nlm.nih.gov/42445731/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Ketamine (KET) addiction has already been a serious problem all over the world, which could induce neurological and psychological harm.\u2026", "relevance": { "relevant": true, "reason": "Ketamine addiction treatment in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "3d64557e345ab925f6a31efb0f5a96e26739d60618ca32527701831ee7e3fd07", "title": "Longitudinal dream-content shift and void-like dissociative phenomenology around outpatient ketamine infusions in chronic low back pain: a case report.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1186/s13256-026-06175-9", "url": "https://pubmed.ncbi.nlm.nih.gov/42443960/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Altered-state phenomenology around ketamine may relate to longer-term changes in imaginal processes, but observations across routine care are scarce. We report an educational case focusing on pre-defined dream motifs over time, without making treatment efficacy claims.\u2026", "relevance": { "relevant": true, "reason": "Ketamine for chronic pain, case report on phenomenology.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "285db0edf0c29c1b5a2f39e9b352c6268f917bdf0158dfe3bb6f1ae27ab224b4", "title": "Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation", "compound": "ketamine", "type": "observational", "institution": "University of California, San Diego", "condition": "depression", "sample_size": 56, "status": "recruiting", "date": "2026-01-09", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07396220", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The purpose of this study is to examine the effects of combined intranasal esketamine with brief cognitive behavioral therapy for suicide prevention (BCBT-SP) for suicidal ideation (SI) in patients with treatment- resistant depression (TRD).\u2026", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression and suicidal ideation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "bd70b8bb1543bd66f7c1897e2572854eaa7b9d96585d08e1e87e4bbd41f81942", "title": "A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects", "compound": "ketamine", "type": "phase_1", "institution": "Supernus Pharmaceuticals, Inc.", "condition": "other", "sample_size": 22, "status": "completed", "date": "2018-09-24", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03771586", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "This study is a phase 1, double-blind, placebo-controlled crossover study of single, oral dose of SAGE-718 using a ketamine challenge, to evaluate the electrophysiology, safety, tolerability, and pharmacokinetics in healthy subjects", "relevance": { "relevant": true, "reason": "Human study on safety, tolerability, and pharmacokinetics", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "105d1f86959bcc7b4a4d37fbf434795965e8a804b351e45d2455bc6324d5238c", "title": "Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation", "compound": "ketamine", "type": "phase_3", "institution": "University of Ottawa", "condition": "other", "sample_size": 20, "status": "active", "date": "2023-06-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05468840", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "Approximately 20% of Canadian adolescents experience thoughts of suicide, or suicidal ideation (SI), and suicide is the second leading cause of death among Canadians aged 15-19 years. The emergency department at CHEO sees approximately four patients per day with SI.\u2026", "relevance": { "relevant": true, "reason": "Ketamine for suicidal ideation in adolescents, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "812618b0fa5381b6b58cfc88ddaaf7fbe89f114311cbeddda5a67e74c0043ded", "title": "Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression", "compound": "ketamine", "type": "observational", "institution": "The Cleveland Clinic", "condition": "depression", "sample_size": 15, "status": "completed", "date": "2015-08-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02522377", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "In this proof of concept study, the investigators plan to administer iv ketamine interleaved with ECT days. Patients with treatment resistant depression who are deemed to be eligible for ECT treatment will randomly be assigned to either ketamine or active placebo.", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "c31ffa627ab9621bf457cf16e0c1132150619be470929ff597adff64c598b174", "title": "ED Treatment of Suicidal Patients With Ketamine Infusion", "compound": "ketamine", "type": "phase_2", "institution": "University of California, Davis", "condition": "other", "sample_size": 0, "status": "completed", "date": "2019-04-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03502551", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "This study aims to determine if a single intravenous (IV) dose of ketamine given in the emergency department (ED) can provide a long term reduction in suicidal ideation, lower time to ED discharge, and increase discharge to home or voluntary treatment facilities all while being safe.", "relevance": { "relevant": true, "reason": "Ketamine for suicidal ideation in ED patients is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e73f9bf74ff7fdc1fa85fd856e20806d6bf7659c00c5c69270f77ce05d848608", "title": "Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression", "compound": "ketamine", "type": "phase_2", "institution": "VA Office of Research and Development", "condition": "depression", "sample_size": 44, "status": "recruiting", "date": "2025-12-03", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06419439", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "This is a pilot study to evaluate the feasibility, acceptability, and safety of ketamine infusions followed by a brief behavioral intervention in Veterans with chronic low back pain and depression.", "relevance": { "relevant": true, "reason": "Ketamine for chronic pain and depression in veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "9a9297f62c25662dc57b4d146b44b5a5df7d0eadd1f31827c41326d371c24ec7", "title": "Observational Study of Ketamine Infusions for the Treatment of Chronic Pain", "compound": "ketamine", "type": "observational", "institution": "Theresa Lii", "condition": "other", "sample_size": 100, "status": "recruiting", "date": "2022-06-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05477004", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "This observational study will collect prospectively specified data on patient characteristics and clinically relevant outcomes in patients who receive a ketamine infusion at Stanford Pain Management Center for the treatment of chronic pain, with the goal of identifying treatment responders and relationships between patient characteristics and treatment response.", "relevance": { "relevant": true, "reason": "Observational study of ketamine for chronic pain treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "51643a9af25b52885fee6af820371d7a2901cfc88ad622bd205731e98e41c3ed", "title": "Naturalistic Study of Ketamine in the Treatment of Depression", "compound": "ketamine", "type": "observational", "institution": "Hospital de Clinicas de Porto Alegre", "condition": "depression", "sample_size": 90, "status": "active", "date": "2021-05-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05249309", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "This study aims to examine the effect of ketamine in decreasing the risk of suicide in patients with depression and its effectiveness as an antidepressant agent.", "relevance": { "relevant": true, "reason": "Naturalistic study of ketamine for depression treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "9c3be98ab17105b64bec1965f3370afcded02fb22f7475321cb02579eb54c473", "title": "A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression", "compound": "ketamine", "type": "phase_2", "institution": "Janssen Research & Development, LLC", "condition": "depression", "sample_size": 30, "status": "completed", "date": "2012-06-27", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01640080", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "8c6feafa7b3943389c71e9b20fc5dbad632a7b0e8e81577e24fa862a1bce56e3", "title": "KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study", "compound": "ketamine", "type": "phase_1", "institution": "Helsinki University Central Hospital", "condition": "depression", "sample_size": 12, "status": "recruiting", "date": "2026-03-04", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07462559", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "Ketamine is a dissociative anesthetic developed approximately 60 years ago. Both ketamine and its isomer, esketamine, have been used for over 20 years in the treatment of treatment-resistant depression.\u2026", "relevance": { "relevant": true, "reason": "Ketamine used for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "822029f1fafbaa8d233a6421e91249108d9989d9d505255c9f3211c68db9a578", "title": "Enhancing Week-long Psychological Treatment for PTSD With Ketamine", "compound": "ketamine", "type": "phase_2", "institution": "Yale University", "condition": "PTSD", "sample_size": 162, "status": "recruiting", "date": "2023-08-21", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05737693", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The purpose of this study is to test if the combination of ketamine, vs midazolam, with an intensive trauma-focused psychotherapy will be more effective in relieving post-traumatic stress disorder (PTSD).\u2026", "relevance": { "relevant": true, "reason": "Ketamine used to treat PTSD in a human study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e60d52d0370c9f5fe92df1ba0f244de2352d02a9e1c8b9a7c75c4b45cf52e8f0", "title": "Lidocaine-Ketamine for Management of Chronic Pain", "compound": "ketamine", "type": "observational", "institution": "Hamilton Health Sciences Corporation", "condition": "other", "sample_size": 72, "status": "active", "date": "2017-09-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03249025", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "Chronic pain is defined as 'an unpleasant sensory and emotional experience associated with actual or potential tissues damage, or described in terms of such damage\".\u2026", "relevance": { "relevant": true, "reason": "Ketamine used for chronic pain management in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "c764c6bacde8b54b8f156fdf1ed6c27675508fda1ada21fcf7936c70a64823f5", "title": "Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC", "compound": "ketamine", "type": "observational", "institution": "Centre Leon Berard", "condition": "other", "sample_size": 81, "status": "completed", "date": "2021-02-02", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04459234", "source": "ClinicalTrials.gov", "first_seen": "2026-07-20", "abstract": "The primary objective of this study is to describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication (neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation\u2026) and administration protocol (route, posology, duration, administration sequence, premedication).\u2026", "relevance": { "relevant": true, "reason": "Ketamine for refractory chronic pain in cancer patients.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "881a737ce5636fd35046a1110d91e11caaeedddd2c9f8b1d74f9fa7ccaac0564", "title": "Antidepressant-like effects of ketamine involve CX(3)CL1/CX(3)CR1 signaling-mediated synaptic plasticity in the mPFC.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-02", "outcome_summary": null, "doi": "10.1038/s41398-026-04242-9", "url": "https://pubmed.ncbi.nlm.nih.gov/42477312/", "source": "PubMed", "first_seen": "2026-07-22", "abstract": "Ketamine, a non-competitive N-methyl-D-aspartate acid (NMDA) receptor antagonist, produces rapid and sustained antidepressant actions, but the underlying molecular mechanism remains unclear.\u2026", "relevance": { "relevant": true, "reason": "Antidepressant effects of ketamine in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "dece236606f412218fa82fe3313dacd5bd76f5904f5af8c62950bcc6a9773e8d", "title": "A Study to Decrease Suicidal Thinking Using Ketamine", "compound": "ketamine", "type": "phase_3", "institution": "United States Naval Medical Center, San Diego", "condition": "depression", "sample_size": 0, "status": "completed", "date": "2016-08-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02418702", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "Depression treatment typically is slow acting. Patients presenting with acute suicidality have few immediate treatment options. However, sub-anesthetic doses of ketamine have been now widely tested as a rapid-acting treatment for depression.\u2026", "relevance": { "relevant": true, "reason": "Ketamine for depression and suicidal thinking in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "1ed0c8a9680b981813e9674822bdd2e761a4dcfebcb42129271f9c660ed3c8e2", "title": "Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)", "compound": "ketamine", "type": "phase_2", "institution": "Icahn School of Medicine at Mount Sinai", "condition": "PTSD", "sample_size": 30, "status": "completed", "date": "2015-05-18", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02397889", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The purpose of this study is to study new ways to treat post-traumatic stress disorder (PTSD). Current treatments for PTSD do not work for everyone and it can take time to determine whether a person responds to a chosen treatment.\u2026", "relevance": { "relevant": true, "reason": "Ketamine for PTSD is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "d20e845131dc3fd09a2db767bddf93e203f86bd86f2fe113a5e38eb42557d786", "title": "Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)", "compound": "ketamine", "type": "observational", "institution": "Janssen Research & Development, LLC", "condition": "depression", "sample_size": null, "status": "active", "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03829579", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "This is a pre-approval access program (PAAP) for eligible participants.\u2026", "relevance": { "relevant": true, "reason": "Pre-approval access for esketamine in TRD", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "82312ece2d7cb835a12d06468fe6a73e70fe3a281a59a29d434ab818999bba71", "title": "Treatment of Suicidal Ideation With Intravenous Ketamine Infusion", "compound": "ketamine", "type": "observational", "institution": "University of Alabama at Birmingham", "condition": "depression", "sample_size": 18, "status": "completed", "date": "2012-05-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01887990", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "This study is dedicated to achieving better treatments for suicidal thoughts. Specifically, the investigators are studying the effect of a medication called ketamine to quickly treat suicidal thoughts and depression.", "relevance": { "relevant": true, "reason": "Ketamine for suicidal ideation and depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "b393179887e25da03d4d2844c8199ea0628e56f3ef425b59fa013e8f339f1512", "title": "Ketamine for Opioid Use Disorder", "compound": "ketamine", "type": "phase_2", "institution": "University of Maryland, Baltimore", "condition": "addiction", "sample_size": 50, "status": "recruiting", "date": "2026-02-04", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06943859", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The goal of this clinical trial is to learn if ketamine works to reduce craving for opioids in adults entering methadone treatment for opioid use disorder. The main questions it aims to answer are: * Does ketamine reduce craving for opioids in patients with opioid use disorder?\u2026", "relevance": { "relevant": true, "reason": "Ketamine for opioid use disorder, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "a37961ab5a29245746af4eeb0e8b5ad527c657a544d9812cd1bec87c5b4b4ac0", "title": "Ketamine for Depression and Alcohol Dependence", "compound": "ketamine", "type": "phase_1", "institution": "Yale University", "condition": "depression", "sample_size": 5, "status": "completed", "date": "2012-03-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01551329", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence.\u2026", "relevance": { "relevant": true, "reason": "Ketamine for depression and alcohol dependence in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "0ce8bb814a0f7a9d47ffbdd3f3fb9d3423701609519c4835f1f26228d85e069a", "title": "Understanding Ketamine's Dissociative Effects (KD Study)", "compound": "ketamine", "type": "phase_1", "institution": "Stanford University", "condition": "other", "sample_size": 20, "status": "recruiting", "date": "2021-07-26", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04861051", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The purpose of this study is to understand how ketamine brings about dissociative symptoms.", "relevance": { "relevant": true, "reason": "Mechanism of action study of a dissociative compound.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "913c226253554e229eabd7c3172489b057951df7bbaf002c4550e4fd5b6fb4b6", "title": "Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine", "compound": "ketamine", "type": "observational", "institution": "King's College London", "condition": "depression", "sample_size": 27, "status": "completed", "date": "2021-09-27", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04977674", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The overarching aim of this research is to determine the acute effects of ketamine on brain glutamate, functional connectivity and cerebral blood flow in treatment-resistant depression, explore whether the effects are attenuated by the opioid receptor antagonist naltrexone and relate these findings to antidepressant response.", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression, exploring glutamate and opioid mechanisms.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "b27bf3733c845d34dc8a8872502d50fce85de5b05824266ff6a40afb7a1a9a40", "title": "Intranasal Ketamine for Suicidal Ideation in Veterans", "compound": "ketamine", "type": "observational", "institution": "Bronx Veterans Medical Research Foundation, Inc", "condition": "other", "sample_size": 0, "status": "completed", "date": "2020-01-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03788694", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The objective of the current study is to investigate the safety, efficacy, and feasibility of multiple doses of intranasal (IN) ketamine for suicidal ideation Veterans.", "relevance": { "relevant": true, "reason": "Ketamine for suicidal ideation in human veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "c5dd1dd772fabec854b3a9e72a807696feb850c73c4b375b2fdc08bb4e943b2c", "title": "A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression", "compound": "ketamine", "type": "phase_2", "institution": "Janssen Pharmaceutical K.K.", "condition": "depression", "sample_size": 202, "status": "completed", "date": "2016-12-12", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02918318", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD), in improving depressive symptoms.", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "c2d789d69ba61733f1f6334c593bcc9ffaa551b3957697946c3a6ca25f3f7491", "title": "Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic", "compound": "ketamine", "type": "observational", "institution": "Limbic Medical", "condition": "other", "sample_size": 30, "status": "active", "date": "2020-04-15", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04769297", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "A retrospective chart review of an open-label trial of low-dose ketamine administered to front-line Healthcare workers who were identified as experiencing acute stress disorder due to the COVID-19 Pandemic.", "relevance": { "relevant": true, "reason": "Ketamine for acute stress disorder in healthcare workers.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "0c42cbc1f7041a6dd8e872e657a2880a380eb73a7ea09222f364570cae5ea048", "title": "Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder", "compound": "ketamine", "type": "phase_1", "institution": "Wayne Goodman MD", "condition": "OCD", "sample_size": 3, "status": "completed", "date": "2012-06-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01371110", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "Obsessive-Compulsive Disorder (OCD) is a chronic and disabling anxiety disorder and a leading cause of worldwide disability that presents a significant public health problem.\u2026", "relevance": { "relevant": true, "reason": "Ketamine for OCD, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "594f1fa5ddf7290c80d689f9fbaaddbccb976d991e3bf64d8666a1bf95dd541f", "title": "Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine", "compound": "ketamine", "type": "observational", "institution": "Psych Atlanta", "condition": "depression", "sample_size": 10, "status": "completed", "date": "2018-09-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04856124", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "This study aims to assess the efficacy and safety of intranasal esketamine as maintenance antidepressant therapy in patients who have demonstrated clinical improvement with off-label intravenous racemic ketamine for treatment-resistant depression.", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression maintenance therapy.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "ada032b235a8b49d7e0afeb1c46caeb51e009dca5fddbd64c5f937a24edb75b7", "title": "Oral Ketamine for Control of Chronic Pain in Children", "compound": "ketamine", "type": "phase_1", "institution": "University of Rochester", "condition": "other", "sample_size": 12, "status": "completed", "date": "2011-05-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01369680", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "The study is a maximum tolerated dose finding study for oral, chronic, daily administration of oral ketamine (by mouth) in children with long-term daily pain.", "relevance": { "relevant": true, "reason": "Oral ketamine for chronic pain in children.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "4b4fcd03fc9aefa5519f05d904e40ca39524b7e78da95549febca837ed0879b8", "title": "atai\u2019s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase 2a Trial", "compound": "ketamine", "type": "phase_2", "institution": "atai Life Sciences", "condition": "depression", "sample_size": null, "status": "completed", "date": "2026-07-22", "outcome_summary": "PCN-101 did not meet its primary endpoint of a statistically significant change in MADRS at 24 hours versus placebo, though it showed efficacy signals across all timepoints up to two weeks and was generally well tolerated.", "doi": null, "url": "https://psychedelicalpha.com/news/atais-pcn-101-candidate-fails-to-meet-primary-endpoint-in-heavily-anticipated-phase-2a-trial", "source": "Psychedelic Alpha", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Investigational treatment for depression, met primary endpoint.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "6d5dec26f498a2d9e64c61ac4e307c9dc2a537783a2932ca747f1aa6b97c0479", "title": "ASAM 2026: Ketamine Shows Potential as Dual-Target Treatment for Comorbid MDD and AUD", "compound": "ketamine", "type": "news", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-22", "outcome_summary": "The systematic review of 8 studies found that ketamine reduced relapse rates in 44% of studies, lowered depression scores in 77% of studies, and decreased alcohol cravings in 67% of studies, with sustained antidepressant effects lasting at least 4 weeks in participants with a family history of AUD.", "doi": null, "url": "https://www.psychiatryadvisor.com/news/ketamine-shows-dual-target-potential-for-patients-with-comorbid-mdd-and-aud", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Ketamine for MDD and AUD treatment in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "ab9f556f7ab6c84a603bba684f47eecb0fba9491cf4c000dd0ed19ee52a20df7", "title": "Phase 1 Depressive Disorder 2024", "compound": "ketamine", "type": "phase_1", "institution": null, "condition": "depression", "sample_size": null, "status": null, "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://www.withpower.com/trial/phase-1-depressive-disorder-2024-e27e3", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Phase 1 study for depressive disorder", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "2c0677d1bfcfba99b89a005cd4e55dc521ef4fb156760cd49dfea329a4926776", "title": "Drug combo is the first to prolong ketamine\u2019s antisuicide effects", "compound": "ketamine", "type": "news", "institution": "Stanford Medicine", "condition": "depression", "sample_size": 45, "status": "completed", "date": "2026-07-22", "outcome_summary": "In a placebo\u2011controlled trial of 45 patients with major depressive disorder and suicidal ideation, low\u2011dose buprenorphine given daily for four weeks after a ketamine infusion extended the drug\u2019s antisuicide effects. 78% of the buprenorphine group remained responsive after one month versus 48% of the placebo group, with greater reductions in suicidality scores.", "doi": "10.1176/appi.ajp.20250840", "url": "https://med.stanford.edu/news/all-news/2026/05/drug-ketamine-antisuicide-effects.html", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Ketamine for depression and suicidal ideation in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "15d4377a54e069c88721effe23e2d51b71f874796b5b1bd37ea9e538cc5524fd", "title": "Ketamine's promise for severe depression grows, major questions remain", "compound": "ketamine", "type": "news", "institution": "Michigan Medicine", "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-22", "outcome_summary": "The article reports that ketamine shows promise in treating severe depression, but more research is needed to address questions about long\u2011term efficacy, safety, and optimal dosing.", "doi": null, "url": "https://www.michiganmedicine.org/health-lab/ketamines-promise-severe-depression-grows-major-questions-remain", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Ketamine for severe depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "5334b10d1d5334d19a0aa3236b01df93207fc27908be00386552efb6ad466414", "title": "DATAd: A new communication and tracking system for treatment-resistant depression.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-17", "abstract": "Treatment-resistant depression (TRD) carries a substantial personal and societal burden, yet no universally accepted definition or communication framework exists to guide its clinical management.\u2026", "outcome_summary": null, "doi": "10.1016/j.jad.2026.122266", "url": "https://pubmed.ncbi.nlm.nih.gov/42468852/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Treatment-resistant depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "f157c9c183ca46996779beec745c56b0eeb105dafba1511c57386929e9edf5b5", "title": "miR-206-mediated Regulation in Depression: From Pathophysiological Mechanisms to Intranasal AntagomiR-206 Therapy.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-08", "abstract": "Depression is a globally prevalent mental disorder characterized by persistent low mood and cognitive deficits, with high incidence and recurrence rates, causing a heavy burden on individual health and public health systems worldwide.\u2026", "outcome_summary": null, "doi": "10.2174/0118715273480036260623080843", "url": "https://pubmed.ncbi.nlm.nih.gov/42458953/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Depression is a psychiatric indication, and the study explores therapeutic mechanisms.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "f4664018b60957fea448a3a7d187d8e52a8460a7761180a8e7e57b80d501477f", "title": "Initiating dextromethorphan-bupropion extended release in patients with major depressive disorder: Delphi panel expert consensus recommendations.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-15", "abstract": "To establish consensus recommendations for initiating dextromethorphan-bupropion extended release (45 mg/105 mg) (AUVELITY) for the treatment of major depressive disorder (MDD) in adults.\u2026", "outcome_summary": null, "doi": "10.1080/03007995.2026.2700073", "url": "https://pubmed.ncbi.nlm.nih.gov/42454904/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Dextromethorphan-bupropion for major depressive disorder treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "473b908fcc327e1ea549de869494ab0027ec10c60bf63d955c4b864137cc7ee8", "title": "Ionic Homeostasis Failure in Major Depressive Disorder: Ion Channel Mechanisms, Excitation-Inhibition Imbalance, and Precision Therapeutics.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-07", "abstract": "Major depressive disorder (MDD) remains a leading cause of disability; however, monoaminergic models do not fully explain delayed treatment onset, incomplete remission, or rapid responses to glutamatergic interventions. In this study, we proposed a system-level ionic homeostasis framework for MDD.\u2026", "outcome_summary": null, "doi": "10.3390/ijms27136084", "url": "https://pubmed.ncbi.nlm.nih.gov/42450349/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Discusses MDD and glutamatergic interventions, relevant to psychiatric treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "ceea34612cf840d02517266f47d77f03a807b9e76ad2fc1ad184a1ddf6095cef", "title": "Enhancing plasticity to treat depression and other central nervous system diseases using event-driven pharmacology.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-01", "abstract": "The occupancy-driven pharmacology model in psychopharmacology has guided drug discovery and development for decades, whereby the goal is stable receptor occupancy over an extended period with a direct relationship of drug exposure to pharmacodynamic and therapeutic response.\u2026", "outcome_summary": null, "doi": "10.1177/02698811261456206", "url": "https://pubmed.ncbi.nlm.nih.gov/42438931/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Enhancing plasticity to treat depression and CNS diseases.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "278942036b9f27f28f0c65e18ecb3ea91c8d3ef87833b07318c2c62a14dabc43", "title": "BDNF and GSK-3\u03b2 signaling in depression: molecular mechanisms underlying neural plasticity dysfunction.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-08", "abstract": "Depression, a complicated psychiatric condition, is characterized by persistent low mood, disrupted emotional regulation, and cognitive impairment.\u2026", "outcome_summary": null, "doi": "10.1007/s11033-026-12110-4", "url": "https://pubmed.ncbi.nlm.nih.gov/42417900/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Depression is a psychiatric indication, and BDNF/GSK-3b are molecular mechanisms.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "abcac1a9c695dafdd5e4df00869a41a473059317a28e2c0849ea527b792dc587", "title": "Comparative efficacy and acceptability of pharmacological interventions for postpartum depression: a systematic review and network meta-analysis.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-01", "abstract": "Pharmacological treatment for postpartum depression (PPD) have mainly involved conventional antidepressants, RCTs have also evaluated rapid-acting glutamatergic agents, neuroactive steroids, hormonal therapies, and botanical preparations.\u2026", "outcome_summary": null, "doi": "10.1016/j.psychres.2026.117318", "url": "https://pubmed.ncbi.nlm.nih.gov/42401022/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Systematic review of pharmacological treatments for postpartum depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "08827eb3919e9fb7e1a578c6a2dce9b14705f5ec3da55e1c8bcf9d7db21fa0ac", "title": "Mitochondrial-inflammation crosstalk in major depressive disorder: molecular mechanisms and therapeutic implications.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-03", "abstract": "Despite its high prevalence, the precise mechanisms underlying major depressive disorder (MDD) remain incompletely understood.\u2026", "outcome_summary": null, "doi": "10.1038/s41380-026-03732-y", "url": "https://pubmed.ncbi.nlm.nih.gov/42399415/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "MDD is a psychiatric indication, and the paper discusses therapeutic implications.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "89d7735ca58e6b7e146b553373968b14730dadd09bbc0e630b35ac6aeb6507b0", "title": "Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of atai\u2019s PCN-101 Phase 2a Readout", "compound": "ketamine", "type": "phase_2", "institution": "Perception Neuroscience (part of the atai platform)", "condition": "depression", "sample_size": null, "status": "active", "date": "2022-11-17", "abstract": "This week, Psychedelic Alpha's Noah Smith takes a look ahead to one of the most eagerly anticipated data readouts of the year,", "outcome_summary": "The article discusses the development of PCN-101 (R-ketamine or arketamine) by Perception Neuroscience for treatment-resistant depression, ahead of its Phase 2a data readout. It also provides background on ketamine and its enantiomers, S-ketamine (Spravato) and R-ketamine.", "doi": null, "url": "https://psychedelicalpha.com/news/racing-beyond-racemic-a-look-at-ketamine-drug-development-ahead-of-atais-pcn-101-phase-2a-readout", "source": "Psychedelic Alpha", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "R-ketamine for treatment-resistant depression", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } } ], "lsd": [ { "id": "76e09cfff4cf81307f63fe9b1d831be15def8d692c663c82d4f18fd6ebd942b8", "title": "Mood Effects of Serotonin Agonists: Depression", "compound": "lsd", "type": "observational", "institution": "University of Chicago", "condition": "depression", "sample_size": 41, "status": "completed", "date": "2025-06-09", "abstract": "This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 \u00b5g), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07017478", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "LSD for depression in humans, including EEG analysis.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "30392dbba9ef4eb3ecb081e9c621711c74e80d1c81be82aee28129c3f07161cc", "title": "Drug Effects on Mood and Behavior - Expectancy", "compound": "lsd", "type": "observational", "institution": "University of Chicago", "condition": "other", "sample_size": 42, "status": "completed", "date": "2025-06-26", "abstract": "This study will examine the effects of a single low dose of the 5HT2A agonist LSD (Lysergic Acid Diethylamide) (13 \u00b5g) or placebo in individuals who are or are not explicitly told what drug they will receive.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07061886", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Human study on LSD for mood and behavior effects.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "5ad24e164337244024554c6ed38a2b44d8198dc2a894e584a18735ce35c2a505", "title": "'Wired For Worry': LSD Pharma Firm Launches Therapist-Targeted Education Campaign", "compound": "lsd", "type": "news", "institution": "Definium Therapeutics", "condition": "anxiety", "sample_size": null, "status": "other", "date": "2026-07-23", "abstract": "Subscribe today to gain access to every *Research Intelligencer* article we publish as well as the exclusive daily newsletter, full access to *The MediaPost Cases*, first-look research and daily insights from Joe Mandese, Editor in Chief. # Become a free MediaPost member now to read this article.\u2026", "outcome_summary": "Definium Therapeutics has launched an unbranded educational campaign called 'Wired for Worry' targeting mental healthcare providers. The campaign aims to educate them about Generalized Anxiety Disorder (GAD) and its potential neurobiological underpinnings, as Definium develops an LSD variation (DT120) for treating GAD and major depression.", "doi": null, "url": "https://www.mediapost.com/publications/article/416709/wired-for-worry-lsd-pharma-firm-launches-therap.html", "source": "General News", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "LSD variation for GAD and depression, targeting therapists.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } } ], "dmt": [ { "id": "6452bc29c60327d8359325c5f9539b824e34450992c34475971d9b8536a73d62", "title": "Micro-phenomenology of immersion and perceived presences under DMT.", "compound": "dmt", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-01-01", "outcome_summary": null, "doi": "10.1093/nc/niag015", "url": "https://pubmed.ncbi.nlm.nih.gov/42454183/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Psychedelic compound N,N-Dimethyltryptamine (DMT) is renowned for inducing highly immersive experiences, often including encounters with seemingly sentient presences.\u2026", "relevance": { "relevant": true, "reason": "Phenomenology of DMT in humans", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "90cbd4db3711d845ebb8ca00addf2898860b0ae93df1e2fb15e9687cd6a7be06", "title": "Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers.", "compound": "dmt", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1007/s00213-026-07118-4", "url": "https://pubmed.ncbi.nlm.nih.gov/42443620/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Negative self-referential emotions such as embarrassment and shame play a key role in the psychopathology of psychiatric disorders but are often insufficiently addressed by standard treatments.\u2026", "relevance": { "relevant": true, "reason": "Healthy volunteers studying negative self-referential emotions.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "79d9677d7bdcc7ed4312d1d87fccb0b33b0bd8b32e01bc8642ae4a7c4419432a", "title": "Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)", "compound": "dmt", "type": "phase_1", "institution": "Jon Dean", "condition": "other", "sample_size": 20, "status": "recruiting", "date": "2026-09-01", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07693257", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "abstract": "This study examines how the psychedelic substance DMT affects the human brain when administered by the intravenous (IV) route. DMT is a naturally occurring chemical in the body that is thought to help improve mood when ingested in a continuously monitored medical setting.\u2026", "relevance": { "relevant": true, "reason": "Human study on neural effects of DMT for mood improvement.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "52c1263d1cd038c7626d37128e95b235450ab065dea1dde8c1f7d2e8fc831145", "title": "How the ancestral toad medicine 5-MeO-DMT was manufactured", "compound": "dmt", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-06-15", "outcome_summary": "The article discusses the historical synthesis and traditional use of 5\u2011MeO\u2011DMT, noting its brief psychedelic effects and its emerging interest as a potential rapid\u2011acting treatment for depression by companies such as Beckley PsyTech (now AtaiBeckley).", "doi": "10.1016/j.psyche.2026.100012", "url": "https://chacruna.net/how-the-ancestral-toad-medicine-5-meo-dmt-was-manufactured/", "source": "Chacruna Institute", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "5-MeO-DMT for depression treatment, industry news.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "48008fefcadbe89a1dfaef5f1105ee95b5d4ea7e1dd7e5957ecc5ce51e7094fa", "title": "Clinical Study of GH001 in Depression", "compound": "dmt", "type": "phase_1", "institution": "GH Research Ireland Limited", "condition": "depression", "sample_size": 16, "status": "completed", "date": "2019-11-12", "abstract": "The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in patients with Treatment-Resistant Depression (TRD).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04698603", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Investigational treatment for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "a6ac7d4a968a59de2a52175988a9472bac177922c5d37b0db907a227d0403498", "title": "Pharmacokinetics of GH001 in Healthy Volunteers", "compound": "dmt", "type": "phase_1", "institution": "GH Research Ireland Limited", "condition": "other", "sample_size": 46, "status": "completed", "date": "2021-06-21", "abstract": "The primary objective of this study is to investigate the serum pharmacokinetics of 5-MeO-DMT and its metabolite, bufotenine in healthy volunteers in a double-blind, placebo-controlled, randomized study design with single, inhaled doses of GH001 and in an open-label, non-randomized study design with intra-subject dose-escalation of GH001.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05163691", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Pharmacokinetics of 5-MeO-DMT in healthy volunteers", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "a2a9af0ace53822f5d372c426ec798f7e5461db5393b2dc7ab87d4387650a302", "title": "Trifecta Research Study", "compound": "dmt", "type": "observational", "institution": "Axial Therapeutic Research", "condition": "depression", "sample_size": 52, "status": "active", "date": "2022-08-01", "abstract": "This observational study evaluates the impact of Ibogaine-Magnesium (IM), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), Magnetic e-Resonance Therapy (MeRT), and Physiological Supplementation (PS) on posttraumatic stress disorder (PTSD) and traumatic brain injury-related cognitive symptoms among Special Operations Forces (SOF) combat veterans.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07717866", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Observational study on veterans with PTSD and TBI.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "a2cfec0a69f7f387ba35d2f4fa63a72771e4b0a3d1685c139e17d5e892b3b772", "title": "Trifecta Research Study", "compound": "dmt", "type": "phase_2", "institution": "Johns Hopkins University", "condition": "PTSD", "sample_size": 0, "status": "completed", "date": "2025-09-01", "abstract": "The Special Operations Care-Fund (SOC-F) will sponsor the application of four treatments - hormone replacement, magnetic resonance brain stimulation, ibogaine, and 5-Meo-DMT - to Special Operations Forces veterans with a history of combat deployments, traumatic brain injury, and problems with mental health and cognitive functioning.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06810765", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Ibogaine and 5-Meo-DMT for veterans' mental health.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "317c26c8617d061631570e0fba1c5805b3cd08ca43fbafc9e176b1d4dcf0256e", "title": "P\u03b1+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors\u2019 Ketamine; Cybin Raises $175M", "compound": "dmt", "type": "phase_2", "institution": "Delix Therapeutics", "condition": "depression", "sample_size": 18, "status": "active", "date": "2025-10-31", "abstract": "Delix Therapeutics Posts Early Efficacy Signal for 'Non-Hallucinogenic' Neuroplastogen as FDA Clears At-Home Phase II \u2022 NRx Pharmaceuticals", "outcome_summary": "A Phase Ib study of DLX-001 (zalsupindole) in major depressive disorder showed a 12-point drop on the MADRS at day 8, sustained through day 36, with no serious adverse events or hallucinatory effects. The company is proceeding to a Phase II trial with FDA clearance for at-home dosing.", "doi": null, "url": "https://psychedelicalpha.com/news/p%CE%B1-psychedelic-bulletin-212-delix-posts-early-efficacy-signal-nrx-wants-fda-to-ban-competitors-ketamine-cybin-raises-175m", "source": "Psychedelic Alpha", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Psychedelic treatment for major depressive disorder.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } } ], "ibogaine": [ { "id": "46c455d49b8d131e4b58d5563b585835fe7d12299db6e650abfba13dafddfef5", "title": "Psychedelics and Ibogaine \"Pain Medications\" at the Pharmacy Counter: Implications for Pharmacy Practice.", "compound": "ibogaine", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-01-01", "outcome_summary": null, "doi": "10.2147/JPR.S629049", "url": "https://pubmed.ncbi.nlm.nih.gov/42438816/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": null, "relevance": { "relevant": true, "reason": "Discusses psychedelics as pain medications and pharmacy practice.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "c5f223b433f96f704c184c1c4b745a8d57e4c8b8565cd05c048ca2f69280e260", "title": "ibogaine investigators brochure", "compound": "ibogaine", "type": "news", "institution": "MAPS", "condition": "other", "sample_size": null, "status": "published", "date": "2026-06-30", "outcome_summary": "MAPS released the first open\u2011access Ibogaine Investigator\u2019s Brochure, compiling preclinical, safety, dosing, and observational data to support research and regulatory efforts.", "doi": null, "url": "https://maps.org/2026/06/30/ibogaine-investigators-brochure/", "source": "MAPS.org", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Ibogaine research and regulatory efforts for human treatment.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "6b2d2317c8f5ed4b81247783be4aa74b059eced880685d85713c851fc2edea5f", "title": "Trump\u2019s Executive Order Gives Psychedelic Therapy a Boost", "compound": "ibogaine", "type": "news", "institution": "White House", "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-22", "outcome_summary": "The Trump executive order encourages psychedelic research, especially ibogaine, and allocates $50\u202fmillion for state\u2011run research, but experts warn that evidence gaps and safety concerns remain.", "doi": null, "url": "https://ldi.upenn.edu/our-work/research-updates/trumps-executive-order-gives-psychedelic-therapy-a-boost", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Trump executive order encourages psychedelic research, funding allocated.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e9c5d5e5ed0544141209d821fb1db9797cbed9d0a066389fb1631d2fb1e74953", "title": "FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order", "compound": "ibogaine", "type": "news", "institution": "DemeRx NB", "condition": "addiction", "sample_size": null, "status": "other", "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order", "source": "General News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "FDA regulatory action on mental illness treatments", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } } ], "ayahuasca": [ { "id": "1a3eb0329a372a392557a52e34531a65ed016cb638ba8ed5037616652fece85b", "title": "Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour.", "compound": "ayahuasca", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-17", "abstract": "Suicide remains a leading cause of premature mortality worldwide. Current treatments are limited by delayed onset, durability, or poor tolerability.\u2026", "outcome_summary": null, "doi": "10.1016/j.euroneuro.2026.112888", "url": "https://pubmed.ncbi.nlm.nih.gov/42468074/", "source": "PubMed", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Addresses suicidal ideation, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } } ], "mescaline": [ { "id": "cb0969aabbcd77663708889967f9bf689736c684d40f11f42db12e5c990c8886", "title": "One of the oldest psychedelics meets modern brain imaging", "compound": "mescaline", "type": "news", "institution": "Northeastern University", "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-20", "abstract": "\u201cThe power of mescaline to me is that it is doing something different than other psychedelics,\u201d said doctoral student Noah Cavallaro, who conducted the study with professor Craig Ferris, who specializes in psychology and pharmaceutical sciences at Northeastern.\u2026", "outcome_summary": "New research suggests mescaline may contribute to hallucinations and changes in sensory perception similar to those reported in some psychiatric conditions. Comparing mescaline to other psychedelics like LSD and psilocybin could help pinpoint the neural pathways causing specific hallucinogenic experiences.", "doi": "10.1007/s12264-026-01632-3", "url": "https://news.northeastern.edu/2026/07/20/mescaline-drug-psychedelic/", "source": "General News", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Mescaline research in humans, potential psychiatric links.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } } ], "other": [ { "id": "e052b94a9fe0fab73160a23b8675a127ad5030b7096a6c9f0138f290dc4916cd", "title": "Integrated 5-HT(2A)-TrkB and G protein signaling in serotonergic psychedelic responses.", "compound": "other", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-01", "outcome_summary": null, "doi": "10.1038/s41380-026-03746-6", "url": "https://pubmed.ncbi.nlm.nih.gov/42463904/", "source": "PubMed", "first_seen": "2026-07-20", "abstract": "Serotonergic psychedelics have attracted considerable interest as promising therapeutic agents.\u2026", "relevance": { "relevant": true, "reason": "Mechanism of action of serotonergic psychedelics", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "1239de5edecdbae97758b7c97ac729e93d293f67bf66e5651400b6628cfd8369", "title": "2026 Second Quarter Policy & Advocacy Wrap-up", "compound": "other", "type": "news", "institution": "MAPS", "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-08", "outcome_summary": "MAPS partnered with Colorado and Ohio to deliver free statewide psychedelic crisis assessment and intervention training for first responders, becoming the first state to license the program and expanding training to behavioral health, law enforcement, and EMS professionals.", "doi": null, "url": "https://maps.org/2026/07/08/2026-second-quarter-policy-advocacy-wrap-up/", "source": "MAPS.org", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Policy and advocacy news regarding psychedelic training for first responders.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "b680cce791db7fe88dc7f284e4863ef683202e6693c638331f24c39381b6035f", "title": "MAPS Statement on Bipartisan Congressional Letter to FDA", "compound": "other", "type": "news", "institution": "MAPS", "condition": "other", "sample_size": null, "status": "published", "date": "2026-05-04", "outcome_summary": "The statement endorses a bipartisan congressional letter urging the FDA to expedite evaluation of MDMA\u2011assisted therapy for PTSD, calling for clearer guidance on the Special Protocol Assessment process and the integration of psychotherapy.", "doi": null, "url": "https://maps.org/2026/05/04/maps-statement-on-bipartisan-congressional-letter-to-fda/", "source": "MAPS.org", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Regulatory news regarding MDMA-assisted therapy for PTSD.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "dd7fefb6bfc12bcc652b922c7d45390d54709070dafd3283225e00937d7e6ed2", "title": "Exploring the Mental Health Needs of System \u2013 Impacted People", "compound": "other", "type": "meta_analysis", "institution": "MAPS", "condition": "other", "sample_size": null, "status": "published", "date": "2026-04-27", "outcome_summary": "The literature review found that people directly impacted by the criminal legal system have a high prevalence of trauma, substance use disorders, and other complex mental health diagnoses, and that psychedelic\u2011assisted healing may be a potential tool to address these concerns, though significant obstacles remain.", "doi": null, "url": "https://maps.org/2026/04/27/relocating-the-root/", "source": "MAPS.org", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Addresses mental health in system-impacted people with psychedelics.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "9e0cf7ad9f896d530320fbf0b398262c377f757ce9f06e459983a33741348e9e", "title": "Chacruna Institute launches 2026 course on roots of psychedelic therapy, shamanism, ritual and traditional uses of sacred plants", "compound": "other", "type": "news", "institution": "Chacruna Institute for Psychedelic Plant Medicines", "condition": "other", "sample_size": null, "status": "active", "date": "2026-07-22", "outcome_summary": null, "doi": null, "url": "https://chacruna.net/chacruna-institute-launches-2026-course-on-roots-of-psychedelic-therapy-shamanism-ritual-and-traditional-uses-of-sacred-plants/", "source": "Chacruna Institute", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Course on traditional uses of sacred plants and psychedelic therapy.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "330dce071a423253c636fb7d725bcfb34cb1604ae04dc2c213ca75ef94a1910a", "title": "Course: Roots of Psychedelic Therapy, Shamanism, Ritual and Traditional Uses of Sacred Plants 2026", "compound": "other", "type": "news", "institution": "Chacruna", "condition": "other", "sample_size": null, "status": "recruiting", "date": "2026-07-10", "outcome_summary": null, "doi": null, "url": "https://chacruna.net/course-roots-of-psychedelic-therapy-shamanism-ritual-and-traditional-uses-of-sacred-plants-2026/", "source": "Chacruna Institute", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Traditional uses of sacred plants are relevant to psychedelic therapy.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "f15595e7659757990922a7dae1216b50aa0a6e379163956aaf03afa918bd57de", "title": "Psychedelics and Censorship on Social Media", "compound": "other", "type": "news", "institution": "Chacruna Latinoam\u00e9rica", "condition": "other", "sample_size": null, "status": "other", "date": "2026-06-29", "outcome_summary": "Chacruna Latinoam\u00e9rica's Instagram account was permanently deactivated by Meta in 2026 after an opaque appeal process.", "doi": null, "url": "https://chacruna.net/psychedelics-and-censorship-on-social-media/", "source": "Chacruna Institute", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Social media censorship of psychedelic organizations is relevant news.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "0a8656048cb76f6edbc788a990dfdcc202859f549eb55fdd330fc2b5080cf070", "title": "Psycon Denver 2026: Modern Psychedelia Braces for What Comes Next", "compound": "other", "type": "news", "institution": null, "condition": null, "sample_size": null, "status": "published", "date": "2026-05-12", "outcome_summary": null, "doi": null, "url": "https://www.lucid.news/psycon-denver-2026-modern-psychedelia-braces-for-what-comes-next/", "source": "Lucid News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Industry news about the future of psychedelics.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "b01d7e27a05e0a87bb964fa5f089c9c890ed8c1d73bfdf52bb7bd65f9871bb44", "title": "Activists march for cognitive liberty in NYC and advocate in San Francisco", "compound": "other", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-04-24", "outcome_summary": null, "doi": null, "url": "https://www.lucid.news/activists-march-for-cognitive-liberty-in-nyc-and-advocate-in-san-francisco/", "source": "Lucid News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Advocacy for cognitive liberty relates to policy and regulation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "fb7f9af3abe023bbc5f65bf5ad4c31f4646f0c45cfdb1eae325b6c7476a75c7c", "title": "Evaluating the Pros and Cons of State Psychedelic Task Forces", "compound": "other", "type": "regulatory", "institution": "John A. Burns School of Medicine at the University of Hawaii", "condition": "other", "sample_size": null, "status": "active", "date": "2026-04-17", "outcome_summary": "The Hawaii House Health Committee advanced a bill to establish a Mental Health Emerging Therapies Task Force, which will review scientific literature and develop policy recommendations for the safe, ethical implementation of psychedelic therapies such as psilocybin and MDMA.", "doi": null, "url": "https://www.lucid.news/evaluating-the-pros-and-cons-of-state-psychedelic-task-forces/", "source": "Lucid News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "Policy and regulation for psychedelic therapies in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "e27df5a0fe53252e51b99f71088028400b038d01b698e12121cd592c1402cf67", "title": "New Orleans hosts psychedelic research conference double-header", "compound": "other", "type": "news", "institution": "Arrowhead Sci-Tech Conferences & Events", "condition": "other", "sample_size": null, "status": "other", "date": "2026-04-13", "outcome_summary": null, "doi": null, "url": "https://www.lucid.news/new-orleans-hosts-psychedelic-research-conference-double-header/", "source": "Lucid News", "first_seen": "2026-07-22", "abstract": null, "relevance": { "relevant": true, "reason": "News about a psychedelic research conference.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "62e36e2da2f2167739a275f19811ce163a54e229a6ca8a52ae845344be17d836", "title": "A Trial of GH001 in Patients With Treatment-resistant Depression", "compound": "other", "type": "phase_2", "institution": "GH Research Ireland Limited", "condition": "depression", "sample_size": 81, "status": "completed", "date": "2023-05-24", "abstract": "The aim of this randomized, double-blind, placebo-controlled, phase 2b clinical trial is to investigate the safety and efficacy of GH001 (containing mebufotenin \\[5-methoxy-N,N-dimethyltryptamine; 5-MeO-DMT\\]) in patients with treatment-resistant depression (TRD).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05800860", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "GH001 (5-MeO-DMT) for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "a7c6bbbb4a7b2db9e4ee2ffb9f36fb403dc33e38657b30cd99a3bf7b81756ead", "title": "Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults", "compound": "other", "type": "phase_1", "institution": "Advanced Integrative Medical Science Institute", "condition": "depression", "sample_size": 12, "status": "active", "date": "2023-10-01", "abstract": "Phase I safety and dose finding study of a standardized Ayahuasca analog (SM-001) in healthy adult volunteers", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05894902", "source": "ClinicalTrials.gov", "first_seen": "2026-07-22", "relevance": { "relevant": true, "reason": "Phase I safety and dose finding study in healthy adults.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-22" } }, { "id": "fefef78635f9085bb4babd7e1fc2208d4960b573d36ea01ade9b67cd4b5df267", "title": "Midomafetamine Capsules (NDA 215455)", "compound": "other", "type": "regulatory", "institution": "FDA", "condition": "PTSD", "sample_size": null, "status": "approved", "date": "2024-06-04", "abstract": "Farchione, MD Director, Division of Psychiatry Psychopharmacologic Drugs Advisory Committee June 4, 2024 Midomafetamine Capsules (NDA 215455) www.fda.gov 2 Posttraumatic Stress Disorder (PTSD) \u2022 Follows exposure to actual or threatened death, serious injury, or sexual violence \u2022 Intrusive memories, hyperarousal, and avoidant behavior \u2022 Comorbid mood and substance use disorders common \u2022 High risk for suicidal ideation and behavior \u2022 Limited medication options \u2013 Two FDA-approved medications: sertraline and paroxetine \u2013 Response rates rarely exceed 60% \u2013 Less than 20 to 30% of patients achieve full remission \u2022 Unmet need www.fda.gov 3 Psychedelic Drug Development \u2022 Surge in interest, particularly for treatment of psychiatric disorders \u2022 When discussing psychedelics: \u2013 Classic psychedelics (e.g., psilocybin, LSD) \u2013 Midomafetamine \u2022 Schedule I controlled substances \u2022 Prolonged alterations in mood, perception www.fda.gov 4 Midomafetamine for PTSD \u2022 Novel treatment paradigm \u2013 Three sessions of midomafetamine administration \u2013 Psychological intervention \u2022 Preparatory sessions before midomafetamine session \u2022 Medication sessions (with psychological support) \u2022 Integrative sessions after midomafetamine session \u2013 4-month course of treatment \u2022 First of psychedelic drug development program to reach the new drug application stage www.fda.gov 5 Midomafetamine for PTSD \u2022 Investigational new drug application filed in 2001 \u2022 Guidance published in 2023 \u2022 First new drug application for this class www.fda.gov 6 Clinical Trial Data \u2022 Two short-term studies \u2013 Both positive \u2013 Clinically-meaningful improvement \u2022 Long-term follow-up assessment \u2013 Open-label, single-visit \u2013 Appears that effect may be durable \u2022 However, several factors impact interpretability of these results www.fda.gov 7 Functional Unblinding \u2022 Acute effects of midomafetamine make it nearly impossible to blind studies \u2022 Designed and conducted as double-blind studies, but participants able to accurately guess treatment assignment \u2022 Results in expectation bias www.fda.gov 8 Mitigating and Assessing Impact of Bias \u2022 Blinded central raters \u2013 Minimize rater bias \u2022 Unblinding questionnaire \u2013 Assess extent of participant unblinding \u2022 Follow-up assessments \u2013 25% dropout between parent study and follow-up \u2013", "outcome_summary": "Two short-term studies showed clinically meaningful improvement in PTSD symptoms with midomafetamine. A long-term follow-up suggested durable effects, but interpretability is impacted by functional unblinding, dropout rates, and other factors. The contribution of psychotherapy and the safety profile, particularly abuse potential, require further characterization.", "doi": null, "url": "https://www.fda.gov/media/179061/download", "source": "FDA Press Releases", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "PTSD treatment with midomafetamine in human studies.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "855e0be4f08b67dbfcea5f8012c627370cf856bdbed1784b38fb662af9f666dd", "title": "The market for psychedelic drugs to treat mental health conditions gets a big buy signal", "compound": "other", "type": "news", "institution": null, "condition": "other", "sample_size": null, "status": "other", "date": "2026-07-19", "abstract": "# The market for psychedelic drugs to treat mental health conditions gets a big buy signal.\u2026", "outcome_summary": null, "doi": null, "url": "https://www.cnbc.com/2026/07/19/psychedelic-drugs-mental-health.html", "source": "General News", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Industry news about psychedelic drugs for mental health.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "15bf29ed73e3e2c1ff238aa0ff1c3b772374035c1445a868c280cc81333065b9", "title": "Federal Agencies Advance Psychedelic Therapy Following Trump\u2019s Executive Order", "compound": "other", "type": "regulatory", "institution": "Department of Veterans Affairs", "condition": "other", "sample_size": null, "status": "active", "date": "2026-07-22", "abstract": "## Dive deep into the different parts of the cannabis industry with Heady NJ's Finder. # Federal Agencies Advance Psychedelic Therapy Following Trump\u2019s Executive Order. * Breaking NJ Cannabis News, National Cannabis News, Politics and Cannabis Policy.\u2026", "outcome_summary": "President Trump signed an Executive Order to accelerate psychedelic therapy research, allocating $50 million and directing agencies like the FDA, DEA, HHS, and VA to establish pathways for access and collaborate on research. The VA is involved in 20 active clinical trials for conditions like PTSD and depression.", "doi": null, "url": "https://headynj.com/national/federal-agencies-advance-psychedelic-therapy-following-trumps-executive-order/", "source": "General News", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Federal agencies advancing psychedelic therapy research and access.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "67a4bf075afaff238fc7d4535bd6e1283bb037f8a9b639f6d3f8cc75ccd2c750", "title": "Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover", "compound": "other", "type": "news", "institution": "Eli Lilly", "condition": "depression", "sample_size": null, "status": "other", "date": "2026-07-16", "abstract": "## With the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the \u201cbiggest change\u201d for the field of psychiatry. Eli Lilly is acquiring AtaiBeckley in a deal that marks the pharma\u2019s first foray into the emerging psychedelics field.\u2026", "outcome_summary": "Eli Lilly is acquiring AtaiBeckley in a deal that marks the pharma's first foray into the emerging psychedelics field. The deal is valued at up to $3.8 billion, including an upfront payment and a contingent value right.", "doi": null, "url": "https://www.biospace.com/deals/lilly-makes-up-to-3-8b-psychedelics-play-in-ataibeckley-takeover", "source": "General News", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Pharma company's entry into psychedelics field", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } }, { "id": "6b85b00b5800797d5513f8fdd59d2df16c1ade129bad0b88c0deed0e0a50be83", "title": "Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction", "compound": "other", "type": "news", "institution": "Eli Lilly", "condition": "other", "sample_size": null, "status": "other", "date": "2026-07-16", "abstract": "# Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction. * Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion. * AtaiBeckley is developing several psychedelics for mental health conditions.\u2026", "outcome_summary": null, "doi": null, "url": "https://www.cnbc.com/2026/07/16/eli-lilly-to-buy-psychedelics-maker-ataibeckley-2point8-billion.html", "source": "General News", "first_seen": "2026-07-23", "relevance": { "relevant": true, "reason": "Industry news about a psychedelic company acquisition.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-07-23" } } ] } }